Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice

Yue, Grace Gar-Lee; Kwok, Hin‐Fai; Lee, Julia Kin-Ming; Jiang, Lei; Wong, Eric C.; Gao, Si; Wong, Hai Ming; Li, Lin; Chan, K. C. Allen; Leung, Ping‐Chung; Fung, Kwok‐Pui; Zuo, Zhong; Lau, Clara Bik‐San

doi:10.1016/j.phrs.2016.05.025

Cited by 49 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Curcumin (CUR; 1,7-bis(4-hydroxy 3-methoxy phenyl)-1,6-heptadiene-3,5-dione), also called diferuloylmethane, is a diphenolic compound extracted from the rhizome of the perennial herb Curcuma longa (turmeric), a plant which belongs to the Zingiberaceae family 16–18. CUR is a yellow pigment extensively used as a spice, coloring agent and flavoring agent, but also in traditional Asian medicine to treat different types of diseases 6.…”

Section: Introductionmentioning

confidence: 99%

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Tefas

Sylvester

Tomuță

et al. 2017

DDDT

108

View full text Add to dashboard Cite

The aim of this work was to use the quality-by-design (QbD) approach in the development of long-circulating liposomes co-loaded with curcumin (CUR) and doxorubicin (DOX) and to evaluate the cytotoxic potential of these liposomes in vitro using C26 murine colon carcinoma cell line. Based on a risk assessment, six parameters, namely the phospholipid, CUR and DOX concentrations, the phospholipid:cholesterol molar ratio, the temperature during the evaporation and hydration steps and the pH of the phosphate buffer, were identified as potential risk factors for the quality of the final product. The influence of these variables on the critical quality attributes of the co-loaded liposomal CUR and DOX was investigated: particle size, zeta potential, drug loading and entrapment efficiency. For this, a 26−2 factorial design was employed to establish a proper regression model and to generate the contour plots for the responses. The obtained data served to establish the design space for which different combinations of variables yielded liposomes with characteristics within predefined specifications. The validation of the model was carried out by preparing two liposomal formulations corresponding to the robust set point from within the design space and one outside the design space and calculating the percentage bias between the predicted and actual experimental results. The in vitro antiproliferative test showed that at higher CUR concentrations, the liposomes co-encapsulating CUR and DOX had a greater cytotoxic effect than DOX-loaded liposomes. Overall, this study showed that QbD is a useful instrument for controlling and optimizing the manufacturing process of liposomes co-loaded with CUR and DOX and that this nanoparticulate system possesses a great potential for use in colon cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Tefas

Sylvester

Tomuță

et al. 2017

DDDT

108

View full text Add to dashboard Cite

show abstract

“…The mechanisms of bevacizumab targeting therapy include: i) Interference with tumor vessels (15): it breaks binding and activation directly, regulates or inhibits vasculature of tumors and prevents proliferation of tumor vessels. ii) Inhibit tumor differentiation (11): Tumor differentiation factors can operate in the micro-environment of vessel endothelium in the human body and produce angiogenesis effects; bevacizumab can inhibit secretion of tumor differentiation factors effectively and control the formation of new blood vessels from the source, such as cellular hypoxia to cause apoptosis, prevents normalization process of pseudo-vessels.…”

Section: Discussionmentioning

confidence: 99%

Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation

Sun

Jiang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Clinical effects of bevacizumab target therapy in treating early colorectal carcinoma (CRC) after resection were analyzed. Ninety-two patients diagnosed with early CRC and treated with endoscopic mucosal resection for the first time were selected for the study. They were randomly divided into the control group and the observation group with 46 cases in each group. Control group was administered the chemotherapy regimen with oxaliplatin, calcium folinate and 5-fluorouracil, while bevacizumab targeting therapy was given to the observation group. The follow-up median time in these two groups was 30 months. In the observation group, objective response rate and disease control rate were higher than those in the control group, the adverse reaction rate was lower, and the differences were statistically significant (p<0.05). In the observation group, disease-free survival was prolonged (38.6 vs. 30.5 months, p<0.05); the recurrence rate was lower (13.0 vs. 30.4%, p<0.05); the survival rate was improved (91.3 vs. 76.1%, p<0.05). Vascular endothelial growth factor (VEGF) expressions of follow-up serum in these two groups were lower; VEGF expression in the observation group was lower than that in the control group, and the differences had statistical significance (p<0.05). There was no statistical significance in comparison of positive expression in tissue VEGF (p>0.05). In conclusion, after bevacizumab targeting therapy in treating early CRC, VEGF expression of serum was significantly lower; treatment effects improved; adverse drug reaction was reduced; survival time was prolonged; the recurrence rate was reduced; the survival rate improved. It has good application values.

show abstract

“…Curcumin (Figure ), the main curcuminoid of turmeric ( C. longa ), was investigated in HT29 colon tumor‐bearing mice associated with bevacizumab. Turmeric extract‐fed mice gave the highest bioavailability of curcumin, and the combined regimen obtained the best results in terms of antitumor effects without observable side effects (Yue et al, ). The authors suggested that, given the encouraging results in animal model, the adjuvant use of turmeric extract could be a potential therapy for colorectal cancer.…”

Section: Phytotherapeutics As Adjuvant Agents In Conventional Antimetmentioning

confidence: 99%

Phytotherapeutics in cancer invasion and metastasis

Salehi

Zucca

Sharifi‐Rad

et al. 2018

Phytotherapy Research

106

View full text Add to dashboard Cite

Cancer is a multifactorial disease, and therefore, a multitarget approach is needed to face the complex cancer biology, based on the combined use of different natural and synthetic anticancer agents able to target synergistically multiple signaling pathways involved in carcinogenesis, including angiogenesis and metastasis. In this view, the plant kingdom represents an unlimited source of phytotherapeutics with promising perspectives in the field of anticancer drug discovery. This narrative review aims to provide an updated overview on the bioactive phytochemicals exhibiting a promising potential as adjuvants in conventional anticancer therapies, with emphasis on antiangiogenic and antimetastatic activities.

show abstract

Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice

Cited by 49 publications

References 36 publications

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation

Phytotherapeutics in cancer invasion and metastasis

Contact Info

Product

Resources

About